3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Unknown
1
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Breast Neoplasms
30
Carcinoma, Non-Small-Cell Lung
14
Lung Neoplasms
9
Neoplasm Metastasis
3
Neoplasms
2
Hodgkin Disease
2
Adenocarcinoma of Lung
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Thoracic Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Recurrence
1
Pancreatic Neoplasms
1
Mesothelioma
1
Malignant Solid Tumour
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma
1
Lung Diseases
1
Breast Neoplasms, Male
1
Advanced Non-Small Cell Lung Cancer
1
Adenocarcinoma, Bronchiolo-Alveolar
1
Interventions
Pemetrexed
5
Carboplatin
5
Paclitaxel
3
osimertinib
2
Gemcitabine
2
pralsetinib
1
pembrolizumab
1
patritumab
1
napabucasin
1
atezolizumab
1
alectinib
1
Vinorelbine
1
Patient Reported Outcome Measures
1
Nivolumab
1
Metformin
1
Indocyanine Green
1
Erlotinib Hydrochloride
1
Cisplatin
1
Bevacizumab
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Thoracic Neoplasms
×
Vinorelbine
×
Clear all
NCT05583188
2024-07-19
VIGOR
Galvanize Therapeutics, Inc.
Phase 4
Terminated
5 enrolled